Treatment Effectiveness in People With axSpA or PsA Starting Treatment With Bimekizumab, Risankizumab, Guselkumab, Upadacitinib, or a TNF Inhibitor

NCT07166315 · clinicaltrials.gov ↗

RECRUITING

Status

700

Enrollment

INDUSTRY

Sponsor class

Conditions

Axial Spondylarthritis (axSpA)
Psoriatic Arthritis (PsA)

Interventions

OTHER: observational study

Sponsor

Adelphi Real World